

<i>Preface</i>	v
<i>Chapter 1. Adeno-associated viral vectors for gene therapy</i>	1
T. R. Flotte and K. I. Berns	
1.1. Biological properties of adeno-associated virus	1
1.2. AAV-based gene therapy vectors	2
1.3. In vivo applications of rAAV	4
1.4. Clinical experience with rAAV	7
1.5. Persistence of rAAV vectors	8
1.6. Safety of rAAV vector delivery	11
1.7. Host range, alternate serotypes, and capsid modifications	12
1.8. Remaining questions	13
References	13
<i>Chapter 2. Production of research and clinical-grade recombinant adeno-associated virus vectors</i>	19
J. D. Francis and R. O. Snyder	
2.1. Adeno-associated virus biology	20
2.2. rAAV preparation	24
2.3. Protocols	27
2.4. Small-scale rAAV 1, 2, and 5 vector purification	28
2.5. Large-scale rAAV purification	30
2.6. rAAV vector characterization	31
2.7. Safety testing	34
2.8. Pre-clinical regulatory compliance activities	35
2.9. Manufacture of clinical-grade rAAV vectors	38
2.10. Clinical manufacturing regulatory compliance activities	44
References	49

<i>Chapter 3. Gene therapy for hemophilia.</i>	57
C. Mah	
3.1. Non-viral DNA vectors.....	59
3.2. Adenovirus vectors.....	60
3.3. Retrovirus vectors.....	62
3.4. Adeno-associated virus vectors.....	64
3.5. Immunological considerations.....	69
3.6. Laboratory protocols.....	72
References.....	73
 <i>Chapter 4. Recombinant AAV vectors for gene transfer to the lung: a compartmental approach.</i>	 83
T. R. Flotte	
4.1. Introduction.....	83
4.2. Genes, targets and vectors for the lung.....	84
4.3. Therapies targeting the alveoli.....	85
4.4. Therapies targeting the airways.....	87
4.5. Therapies targeting the pulmonary vasculature and pleura.....	92
4.6. Future directions.....	93
References.....	94
 <i>Chapter 5. Adeno-associated virus mediated gene therapy for vascular retinopathies.</i>	 103
B. J. Raisler, W.-T. Deng, K. I. Berns and W. W. Hauswirth	
5.1. Introduction.....	103
5.2. New strategies for treating NV.....	106
5.3. Protocols.....	114
5.4. Discussion.....	118
References.....	119

<i>Chapter 6. Gene therapy for prevention and treatment of type 1 diabetes.</i>	125
M. H. Kapturczak, B. R. Burkhardt and M. A. Atkinson	
6.1. The clinical problem diabetes	125
6.2. Transplantation	126
6.3. Allograft rejection: mechanisms for increasing graft acceptance	127
6.4. Recurrent autoimmunity as a mechanism of β cell allograft failure	129
6.5. Gene transfer into islet cells	131
6.6. Potential utility of rAAV-mediated gene therapy for islet transplantation and prevention of autoimmunity recurrence in type 1 diabetes	136
6.7. Progress in insulin replacement strategies utilizing gene therapy	142
6.8. Summary and future directions	146
References	147
 <i>Chapter 7. Gene therapy for kidney diseases.</i>	 161
S. Chen, K. M. Madsen, C. C. Tisher and A. Agarwal	
7.1. Structure–function correlations	162
7.2. Vector systems for gene delivery	163
7.3. Methods of gene delivery	170
7.4. Targeting specific cells in the kidney	172
7.5. Application of gene therapy for specific kidney diseases	176
References	185
 <i>Chapter 8. AAV for disorders of the CNS</i>	 193
C. Burger, R. J. Mandel and N. Muzyczka	
8.1. Introduction	193
8.2. Parkinson disease (PD)	198
8.3. Alzheimer's disease (AD)	204
8.4. Epilepsy	206

8.5.	Lysosomal storage disorders (LSD)	208
8.6.	Conclusion	212
	References	213
<i>Chapter 9. Gene therapy for cardiovascular applications . .</i>		225
C. A. Pacak, C. Mah and B. J. Byrne		
9.1.	Viral gene delivery systems	227
9.2.	Non-viral gene delivery systems	232
9.3.	Gene delivery route.	233
9.4.	Cellular and gene therapy combinations	234
9.5.	Conclusions	234
9.6.	Methods.	235
	References	239
<i>Chapter 10. Gene therapy for lysosomal storage disorders.</i>		243
K. O. Cresawn and B. J. Byrne		
10.1.	The lysosome	243
10.2.	Lysosomal storage diseases	244
10.3.	Current therapies	244
10.4.	Gene therapy	245
10.5.	Glycogen storage disease type II	248
10.6.	Gene therapy for GSD II: Proof of concept studies.	254
10.7.	Recombinant adeno-associated virus vector studies.	256
10.8.	Recombinant AAV-mediated treatment of GSDII	257
10.9.	Gene therapy for CNS pathologies in LSDs	262
10.10.	Conclusion	265
	References	266
<i>Index</i>		277